1. NIH consensus conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65–9.
2. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis. 1999; 179:1523–30.
3. Kim JG. Treatment of Helicobacter pylori infection. Korean J Gastroenterol. 2005; 46:172–80.
4. Sung H, Chung HJ, Kim MN, Lee GH. Clinical usefulness of antimicrobial susceptibility test for Helicobacter pylori. Korean J Lab Med. 2006; 26:179–84.
5. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16:167–80.
6. Eun CS, Han DS, Park JY, Jeon YC, Hahm JS, Kim KS, et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol. 2003; 38:436–41.
7. Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, et al. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol. 2007; 50:356–62.
8. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol. 2006; 47:337–49.
9. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents. 2006; 28:6–13.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. M100-S9. Wayne, PA; NCCLS,. 1999.
11. Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother. 1999; 43:2747–52.
12. Kang JO, Han D, Choi TY. Evaluation of four methods for antimicrobial susceptibility testing of Helicobacter pylori in routine practice. Korean J Clin Microbiol. 2005; 8:82–9.
13. Lang L, Garcia F. Comparison of E-test and disk diffusion assay to evaluate resistance of Helicobacter pylori isolates to amoxicillin, clarithromycin, metronidazole and tetracycline in Costa Rica. Int J Antimicrob Agents. 2004; 24:572–7.
14. Hachem CY, Clarridge JE, Reddy R, Flamm R, Evans DG, Tanaka SK, et al. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis. 1996; 24:37–41.
15. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect. 2002; 8:388–96.
16. Mishra KK, Srivastava S, Garg A, Ayyagari A. Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods. Curr Microbiol. 2006; 53:329–34.
17. Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974; 130:588–94.
Article
18. Iovene MR, Romano M, Pilloni AP, Giordano B, Montella F, Caliendo S, et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy. 1999; 45:8–14.
19. Weiss K, Laverdière M, Restieri C. Comparison of activity of 10 antibiotics against clinical strains of Helicobacter pylori by three different techniques. Can J Gastroenterol. 1998; 12:181–5.
20. Midolo PD, Bell JM, Lambert JR, Turnidge JD, Grayson ML. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. Pathology. 1997; 29:411–4.
21. Smith C, Perkins J, Tompkins D. Comparison of Etest and disc diffusion for detection of antibiotic resistance in Helicobacter pylori. PHLS Microbiol Dig. 1997; 14:21–3.
22. Grignon B, Tankovic J, Mégraud F, Glupczynski Y, Husson MO, Conroy MC, et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist. 2002; 8:61–6.
23. McNulty C, Owen R, Tompkins D, Hawtin P, McColl K, Price A, et al. Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrob Chemother. 2002; 49:601–9.
24. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. M23-A3. Wayne, PA; CLSI,. 2008.
25. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004; 48:4843–7.
26. Franzin L, Pennazio M, Cabodi D, Paolo Rossini F, Gioannini P. Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. Curr Microbiol. 2000; 40:96–100.
27. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001; 47:459–61.
28. Alarcón T, Domingo D, López-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents. 1999; 12:19–26.